Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

Switching from CD20 inhibitors to fumarate therapies reduces healthcare visits and infection-related costs, while controlling ...

Under the terms of the deal, Bedford, Mass.-based Stoke (STOK) will retain exclusive rights for the treatment called zorevunersen in the U.S., Canada and Mexico, while Cambridge, Mass.-based Biogen ...

Piper Sandler analyst David Amsellem lowered the firm’s price target on Biogen (BIIB) to $135 from $138 and keeps a Neutral rating on the ...

Biogen Inc. has been determined as a “Top Pick” in the biopharma sector due to its strong financial fundamentals, strategic positioning, and promising growth prospects. The company, known for its ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Stock analysts at William Blair increased their Q1 2025 earnings per share (EPS) estimates for shares of Biogen in a research ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Biogen in a research note ...

EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Biogen (BIIB) to $139 from $156 and keeps a Market Perform rating on the ...